Original Article

Percutaneous transhepatic balloon dilatation of benign bilioenteric strictures: Analysis of technique and long-term outcome

Chinmay Bhimaji Kulkarni,* Sreekumar Karumathil Pullara, Srikanth Moorthy, Nirmal Kumar Prabhu, Puthukudiyil Kader Nazar, Ramiah Rajesh Kannan

ABSTRACT

Background: To retrospectively analyze the technique and outcome of percutaneous transhepatic biliary balloon dilatation (PBBD) used to treat benign biliary strictures in a series of patients who had undergone surgery for various pathologies.

Methods: We retrieved the hospital records of 90 patients with benign biliary strictures and identified 38 patients (male:female = 21:17; mean age, 50.7 ± 16.3 years [range, 13–77 years]) with benign biliary strictures, treated by PBBD between 2000 and 2014. The technique, primary patency, secondary patency, clinical success and complications of PBBD were analyzed.

Results: The bilioenteric anastomoses were performed for postcholecystectomy bile duct injury (n = 15, 39.5%), recurrent pyogenic cholangitis (n = 9, 23.7%), patients operated for malignancies (n = 8, 21.1%), choledochal cyst excision (n = 5, 13.2%) and chronic pancreatitis (n = 1, 2.6%). All patients presented with clinical features of cholangitis. The average duration of treatment of PBBD was 3.0 ± 1.1 months (range, 1–24 months). Technical success for balloon dilatation was achieved in 33/38 (86.8%). The primary patency period and secondary patency periods were 32.5 ± 7.8 months and 22.5 ± 6.4 months, respectively. Clinical success was achieved in all patients who underwent complete balloon dilatation treatment. Recurrence was observed in 8.1% of patients. The mean symptom–free survival time was 123.4 months (95% confidence interval, 105.8–141.1 months). One year and 2 year clinical success rate was 92.1% and 83.0%, respectively.

Conclusion: Irrespective of the underlying pathology balloon dilatation provides excellent long term relief from symptoms in patients with benign bilioenteric stricture and should be offered as the first line of management in these patients.

Keywords: Balloon dilatation; Biliary tract; Cholangiogram; Choledochal cyst; Stricture

Introduction

The reported incidence of bilioenteric stricture in patients undergoing biliointerostomy for various bileduct pathologies ranges from 8% to 40%.1–3 The inevitable increase in volumes of hepatobiliary surgery for various benign and malignant diseases will also impact the incidence of this complication. If left untreated it can lead to recurrent cholangitis, liver cirrhosis and portal hypertension.4 The main objective of treatment is to restore and maintain free flow of bile. Surgical revision of bilioenteric stricture is a challenge because of the very short length of bile duct available for repeat anastomosis and also local fibrosis induced by previous surgeries. The success rates for surgical repair decrease with each successive surgical intervention.5–11 Endoscopic treatment, though widely used in benign biliary strictures, may not be feasible in postoperative bilioenteric strictures with altered upper gastrointestinal or bile duct anatomy.12,13 Percutaneous transhepatic management of benign biliary strictures involves repeated balloon dilatations with an indwelling catheter placed for the period of treatment. These techniques are now being widely employed, with varied reported success rates in ductal (76% to 88%) and anastomotic strictures (67% to 73%).14 Most studies consist of relatively small number of patients with limited long-term patency data or describe a patient populations with a mixture of bilioenteric and primary biliary strictures. The aim of our study is to retrospectively analyze the technique and outcome of percutaneous tran-
shepatic biliary balloon dilatation (PBBD) used to treat bilioenteric strictures in a series of patients who had undergone surgery for various pathologies. We also tried to assess the effects of PBBD on liver biochemical parameters.

**Methods**

*Patient population*

Institutional review board approval was taken for this retrospective analysis (Amrita Institute of Medical Sciences and Research Center, Kochi, India). We retrieved the hospital records of 90 patients with benign biliary strictures and identified 38 patients (male:female = 21:17; mean age, 50.7 ± 16.3 years [range,
13–77 years) with benign biliointestinal strictures, treated by percutaneous transhepatic balloon dilatations between 2000 and 2014 at Amrita Institute of Medical Sciences and Research Center. Post-liver transplant biliary strictures and benign strictures treated primarily by stenting were excluded from the study (Fig. 1). Clinical records and images were retrieved from electronic medical record and picture archiving and communication system. The technique, primary patency, secondary patency, clinical success and complications of PBBD were analyzed.

**Intervention technique (Fig. 2)**

All patients were treated with broad spectrum intravenous antibiotics before the procedure. Procedures were performed under intravenous conscious sedation (2.5–5 mg of midazolam and 50–100 mg of fentanyl, administered intravenously). A 10 to 20 mL of 2% lidocaine was administered subcutaneously to achieve local anesthesia. During the procedure, the vital signs of patient were monitored and oxygen was administered if needed. Percutaneous transheptic cholangiogram was performed by puncturing the bile duct using a 22 G Chiba needle (Cook Inc., Bloomington, IN, USA) under fluoroscopic guidance through a right intercostal approach (right duct) or using ultrasound guidance through an epigastric approach (left duct). After puncturing the duct, iodinated contrast material was injected to opacify the intrahepatic bile ducts and to define the level and nature of obstruction. Based on the percutaneous cholangiogram finding, an appropriate duct was selected and punctured if needed. Using a Neff-set (Cook Inc.) a 0.035-inch guidewire was placed in the system. The stricture was crossed in most cases with a combination of 5 Fr Kumpe catheter (Cook Inc.) and 0.035-inch terumo hydrophilic guidewire (Terumo, Tokyo, Japan). A microcatheter (Progreat; Terumo) had to be employed to cross the stricture in a few instances (Fig. 3). After crossing the stricture, dilatation was performed with standard angioplasty balloons. The balloon size was decided based on the cholangiogram. Initially dilatation was performed using 6 to 8 mm balloons. In subsequent sessions larger diameter balloons (10–14 mm) were used based on the cholangiographic finding. Balloon inflation time and pressure were not standardized across the study group. The balloon was inflated slowly until the waist disappeared and care was taken never to exceed burst pressures. Finally, an internal–external biliary drainage catheter (8.5–12 Fr size) (Cook Inc.) was inserted with its tip coiled beyond the site of obstruction. After the procedure, the catheter was set initially to gravity drainage (Fig. 4, 5). The patient was discharged when clinically stable with the catheter capped and internalized. At 2 to 6 weeks intervals, patients returned to our institution for re-evaluation of hepatic function and overall clinical status and underwent repeat biliary catheter exchanges and balloons dilatations if necessary. If clinical success had been achieved then the drainage catheter was capped and the catheter was removed after a further two week trial. The functional/clinical outcome of no symptoms and/or stable liver function tests was adopted as a definitive criterion for catheter removal (Fig. 4). In six patients where stenting was performed, we used uncovered balloon expandable or self-expandable metallic stents. Complications were classified as major and minor according to the guidelines of the Society of Interventional Radiology Standards of Practice Committee.

Fig. 3. (A–G) A 37-year-old female with recurrent pyogenic cholangitis, post-left hepatectomy and hepatico-jejunosomy stricture presenting with cholangitis. Initial cholangiogram showed stricture in sectoral duct (A, arrowhead) and at hepato-jejunosomy site (A, arrow). Sectoral duct stricture crossed (B, arrow) and dilated with 6 mm angioplasty balloon (C, arrow). Initial attempt to cross hepatico-jejunosomy stricture failed, later crossed using Progreat (Terumo) microcatheter (D, arrow) and dilated serially with 6 and 8 mm balloons (two sessions) (E–F, arrows). (G) Magnetic resonance cholangio pancreatography 33 months later shows no significant biliary dilatation.
Definition of terms and study endpoints

Terms
A complete treatment is the time period between the first balloon dilatation to the final removal of drainage catheter. A dilatation session is the dilatation of strictures, performed in a single radiological intervention. One treatment can consist of multiple dilatation sessions. One or more dilatations were performed in the initial admission and thereafter, on follow-up, the patient was admitted again for further dilatation sessions if needed.

Study endpoints
Technical success was defined as restoration of normal antegrade bile flow across the stricture and resolution of the stricture on cholangiogram. Unsatisfactory dilation was defined as residual narrowing or poor/absent flow after dilatation requiring further dilatation sessions in the same treatment period to achieve technical success. Clinical success was defined by decrease in pre-procedural elevated total bilirubin and alkaline phosphatase (ALP) levels to normal values after the intervention, as well as the absence of cholangitis in the first month after treatment. The total bilirubin and ALP levels were measured a day before the procedure and 4 to 6 weeks after the completion of treatment. Primary patency was defined as the time interval from drainage catheter removal to the detection of recurrent symptoms or the last follow-up. Secondary patency was defined as the patency following one...
Statistical analysis

Statistical analysis was performed using IBM SPSS Statistics 20.0 software (IBM Co., Armonk, NY, USA). The data was analyzed using descriptive statistical methods. Comparison between groups was done using Wilcoxon signed-rank test. Differences were considered to be significant if \( P < 0.05 \). Kaplan-Meier curves were generated to determine the symptom-free survival in the patients.

Results

The various causes for which bilioenteric anastomoses were performed in our patients is shown in Table 1. All patients presented with clinical features of cholangitis.

Treatment

Majority of patients (18 patients) underwent two dilatation sessions, eight patients required three sessions, four sessions were required in three patients and four patients were treated with single session of balloon dilatation. The average duration of treatment of PBBD was 3.0 ± 1.1 months (range, 1–24 months) (Table 1).

Table 1 Summary of Treatment Technique and Outcome in Various Aetiologies

| Aetiology                        | Patient (n = 38) | Balloon dilatation | Balloon dilatation + stenting | Average sessions of dilatations | Average duration of treatment (mo) | Primary patency (mo) | Follow-up (mo) |
|----------------------------------|------------------|--------------------|------------------------------|--------------------------------|-----------------------------------|---------------------|---------------|
| Post-cholecystectomy             | 15               | 11                 | 4                            | 2.3 ± 0.8                      | 2.2 ± 2.6                         | 30.5 ± 29.4         | 31.4 ± 31.9   |
| Recurrent pyogenic cholangitis    | 9                | 9                  | 0                            | 3.0 ± 0.9                      | 4.8 ± 7.5                         | 29.5 ± 44.7         | 29.6 ± 32.1   |
| Post-choledochal cyst excision    | 5                | 4                  | 0                            | 1.5 ± 0.6                      | 1.5 ± 1.4                         | 45.8 ± 28.9         | 60.0 ± 6.0    |
| Chronic pancreatitis             | 1                | 1                  | 0                            | 2                              | 3.4 ± 3.4                         | 24                  | 24            |
| Operated for malignancies*        | 8                | 6                  | 2                            | 2.3 ± 0.1                      | 2.9 ± 0.3                         | 33.5 ± 45.7         | 35.5 ± 40.7   |

Values are presented as number only or mean ± standard deviation.

GIST, gastrointestinal stromal tumor.

*Hepatectomy (1) for cholangiocarcinoma and pancreatecoduodenectomy procedure (5) for duodenal GIST; 2; periampullary carcinoma, 2; neuroendocrine metastases, 1.

Table 2 Liver Biochemical Parameters before and after Treatment

| Aetiology                        | Total bilirubin (mg/dL) | Alkaline phosphatase (IU/L) |
|----------------------------------|-------------------------|-----------------------------|
|                                  | Pre-treatment           | Post-treatment              | Pre-treatment               | Post-treatment               |
| Post-cholecystectomy             | 3.23 ± 2.51             | 1.32 ± 1.37                 | 471.41 ± 409.98             | 128.30 ± 120.20              |
| Recurrent pyogenic cholangitis    | 2.10 ± 1.89             | 0.66 ± 0.40                 | 241.10 ± 118.01             | 118.40 ± 83.30               |
| Operated for cholangiocarcinoma   | 12.43 ± 3.89            | 1.90 ± 1.40                 | 955.00 ± 519.29             | 138.20 ± 75.50               |
| Operated for malignancies        | 4.76 ± 4.79             | 0.76 ± 0.45                 | 519.00 ± 250.26             | 123.20 ± 90.18               |
| Chronic pancreatitis             | 13.76 ± 13.94           | 1.23 ± 1.25                 | 400.00 ± 116.22             | 107.80 ± 68.22               |
| Post-choledochal cyst excision    | 8.18 ± 14.44            | 0.76 ± 0.64                 | 449.80 ± 127.03             | 95.80 ± 36.28                |

Values are presented as mean ± standard deviation.

Technical success and clinical success

Technical success for balloon dilatation was achieved in 33/38 (86.8%). The primary patency period and secondary patency period were 32.5 ± 7.8 months and 22.5 ± 6.4 months, respectively.

Clinical success was achieved in all patients who underwent complete balloon dilatation treatment. The mean value of total bilirubin before and after treatment was 7.4 ± 4.8 mg/dL and 1.6 ± 1.7 mg/dL, respectively and the mean value of ALP before and after treatment was 501.5 ± 245.9 IU/L and 117.6 ± 13.6 IU/L respectively. Post-treatment statistically significant (\( P < 0.001 \)) decrease in bilirubin and ALP was observed (Table 2). In one patient with biliary stricture following choledochal cyst excision we were not able to cross the stricture (Fig. 6). In another patient with biliary stricture following excision of duodenal gastrointestinal stromal tumor (GIST), the initial balloon dilatations failed to resolve the stricture and therefore stenting was done in the same treatment session (Fig. 7). These two cases were deemed as technical failure. In addition, three patients refused to have the external drain after initial dilatation sessions and stenting was performed after crossing the stricture. Though the PBBD was not complete in these patients they were also considered as technical failure for statistical analysis. With regard to complications, none of our patients had any major procedure related complications like hemobilia requiring blood transfusion, anastomotic rupture (bile leak), sepsis, pneumothorax or death.

Follow-up

The post treatment mean follow-up period was 31.4 ± 20.1 months (range, 1–140 months; median, 24 months) and was available in all patients who successfully underwent balloon dilatation treatment. Long term follow-up (> 24 months) was avail-
able in 20 patients (54.1%). Recurrent symptoms were observed in 3/37 patients (8.1%) treated by balloon dilatation. In one patient with RPC and bilioenteric stricture, recurrence occurred 18 months post-treatment, for which patient underwent repeat balloon dilatation and follow-up period (36 months) was uneventful. In other two patients (postcholecystectomy) technical success was achieved initially with balloon dilatation but later stenting was done due to recurrent stricture at 10 months and 12 months respectively. Applying Kaplan-Meir curves, the mean symptom free survival time was 123.4 months (95% confidence interval, 105.8–141.1 months). Clinical success rate at one year was 92.1% and at two year was 83.0% (Fig. 8).

Discussion

Benign bilioenteric strictures are an uncommon clinical and radiologic problem requiring repeated treatment and long-term follow-up of patients. Percutaneous transhepatic interventional techniques play an important role in management of this challenging problem. In this study we have tried to analyze the technique and outcome of PBBD in various category of patients who have undergone bilioenteric anastomosis. Uniquely we have tried to analyze whether the underlying disease has impact on the outcome. The outcomes were evaluated both in terms of normalization of biochemical parameters and symptom free survival.

Recurrent pyogenic cholangitis (RPC) is a progressive inflam-
matory disease with recurrent episodes of jaundice and cholangitis. It is characterized by intrahepatic biliary strictures and hepatolithiasis. Left untreated cirrhosis develops and there is increased risk of hepatocellular carcinoma and cholangiocarcinoma. In our series 9/38 patients (23.7%) had bilioenteric strictures following surgery for RPC. We observed that a higher number of dilatation sessions (3.0 ± 0.9) and duration of treatment (4.8 ± 7.5 months; range, 0.73–24 months) was required in these patients for treatment completion as compared to other categories (Table 1). This may be due to the very fibrotic nature of stricture as a result of persistent stasis and recurrent cholangitis characteristic of RPC.

Excellent technical and clinical success was observed in all these patients with primary patency of 29.5 ± 44.7 months. Yoon et al studied the long term patency of metallic stents in patients with RPC and concluded that metallic stents have high occlusion rates and do not offer a long term solution. The most common cause of stent malfunction is stone or sludge formation inside the stent due to the ongoing disease and bile stasis.

Cholecystectomy is the most common cause of postoperative biliary stricture constituting up to 80% cases in some series. Usually these patients are managed with hepaticojejunostomy. In our series, 15/38 patients (39.5%) belonged to this category. Mean duration of treatment was 2.2 ± 2.6 months. Technical and clinical success was achieved in 14/15 patients (93.3%) with primary patency of 30.5 ± 29.4 months. Our results are comparable to other studies. One of the problems in patients requiring repeated interventions is the onset and progression of cirrhosis secondary to chronic cholestasis. Percutaneous approach in the presence of cirrhosis and periductal fibrosis can be challenging and metallic stents, despite their limited patency, may become a justifiable option.

Ramos-De la Medina et al have observed that percutaneous techniques are more likely to fail in patients operated for malignancy than without malignancy. In our series, eight patients had bilioenteric stricture after surgery for a malignancy (cholangiocarcinoma, 3; doudenal gastrointestinal stromal tumor, 2; periamplary carcinoma, 2; neuroendocrine tumor metastasis, 1). The 6/8 patients (75%) showed good technical and clinical success with primary patency of 33.5 ± 45.7 months. In our series bilioenteric strictures in this category responded well to PBBD.

The bilioenteric strictures in patients who undergo choledochal cyst excision pose a special challenge because these patients are relatively young and may require repeated interventions and close follow-up lifelong. In our series, the mean age of patients presenting with symptoms was 18.4 ± 4.5 years (13–25 years) and average time between surgery and stricture formation was 42.6 ± 42.9 months (18–108 months). Technical success was achieved in 4/5 patients (80%) with primary patency period of 45.8 ± 28.9 months. We observed that these patients require relatively lesser dilatation sessions (1.5 ± 0.6) and time of treatment (1.5 ± 1.4) as compared to patients with other etiologies and also had better outcome (Fig. 9, Table 1).

Chronic pancreatitis with distal CBD strictures are usually managed successfully by endoscopic approach with good success rate. Percutaneous approach may be required in patients with proximal biliary and postoperative bilioenteric strictures. In our series, one patient had developed bilioenteric stricture post-pancreaticoduodenectomy. The patient was managed successfully with balloon dilatation (two sessions) and follow-up period (24 months) was uneventful.

In a recent study, DePietro et al showed good long term results by treating the benign biliary strictures with a structured protocol (staged upsizing of internal/external biliary catheters fol-

---

**Fig. 8.** Kaplan-Meier curve for symptom free survival time.

**Fig. 9.** A 13-year-old male with choledochal cyst excision and hepatico-jejunostomy stricture (A, arrow). Stricture dilated with 10 mm (B, arrow), 12 mm (C, arrow) angioplasty balloons (two sessions). Stones in the biliary system (A, arrowhead) cleared with saline flush. Magnetic resonance cholangiopancreatography 54 months later shows wide open hepatico-jejunostomy site (D, arrow).
lowed by cholangioplasty and replacement of optimal size catheter for 6 months). We treated strictures primarily with graded balloon dilatation followed by placement of appropriate sized catheter across the stricture site. Long term patency rates in our study are slightly better as compared to those reported by DePietro et al.29 We used standard angioplasty balloons in all patients. Special high pressure or cutting balloons were not used. The end point of treatment in our study was either cholangiogram which demonstrated no residual stenosis or the absence of cholangitis in the first month after treatment. Biliary manometric perfusion test has been used in some studies to define the end point of the treatment. The manometric perfusion test has shown same efficacy as the clinical findings for predicting long term patency of strictures treated by PBBD.30,31 The technical success of PBBD for benign biliary strictures in literature is 93% to 100%,21,32–34 We achieved a technical success of 86.8% (33/38). The stricture could not be crossed in only one patient. However the three patients who refused to have the external drain were primarily stented after initial balloon dilatation sessions and were considered as technical failures for purpose of statistical analysis. The reported clinical success rate of PBBD for benign biliary strictures is 75% to 94%.21,32,33 In our study clinical success was achieved in all patients who underwent complete balloon dilatation treatment. Though we did not do a formal cost analysis it would be reasonable to assume that the minimally invasive percutaneous approach using standard commonly used devices will be less expensive and definitely less morbid than a major open surgery requiring general anesthesia and intensive postoperative care. Repeated treatment sessions spread over many months, however, demands high degree of patient motivation and compliance.

The limitations of the study are its retrospective nature and lesser number of patients in each category.

Irrespective of the underlying pathology balloon dilatation provides excellent relief from symptoms in patient with bilioenenteric strictures. Our long term results cutting across all categories indicate that percutaneous balloon dilatation should be offered as the first line of management in patients with bilioenenteric strictures.

Conflicts of Interest

No potential conflict of interest relevant to this article was reported.

Acknowledgments

We would like to acknowledge the invaluable advice and unstinting support of our colleagues in the Departments of Medical and Surgical Gastroenterology and Department of Bio-Statistics, Amrita Institute of Medical Sciences. This work would not have been possible without the dedication and skill of our radiology technicians and nursing staff.

References

1. Johnson SR, Koehler A, Pennington LK, Hanto DW. Long-term results of surgical repair of bile duct injuries following laparoscopic cholecystectomy. Surgery. 2000;128:668-77.
2. Moraca RJ, Lee FT, Ryan JA Jr, Traverso LW. Long-term biliary function after reconstruction of major bile duct injuries with hepaticoduodenostomy or hepaticojejunostomy. Arch Surg. 2002;137:889-93.
3. Murr MM, Gigioli JF, Nagorney DM, Hammsen WS, Bstrup DM, Farnell MB. Long-term results of biliary reconstruction after laparoscopic bile duct injuries. Arch Surg. 1999;134:604-9.
4. Sicklick JK, Camp MS, Lillemeke KD, Melton GB, Yeo CJ, Campbell KA, et al. Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg. 2005;241:786-92.
5. Ahrends SA, Pitt HA. General surgical therapy of iatrogenic lesions of biliary tract. World J Surg. 2001;25:1360-5.
6. Lillemeke KD, Melton GB, Cameron JL, Pitt HA, Campbell KA, Talamini MA, et al. Postoperative bile duct strictures: management and outcome in the 1990s. Ann Surg. 2000;232:430-41.
7. Pitt HA, Kaufman SL, Coleman J, White RL, Cameron JL. Benign postbiliary strictures. Operate or dilate? Ann Surg. 1989;210:417-25.
8. Sheridan JS, Maclean AC. Percutaneous transhepatic use of a cutting balloon in the treatment of a benign common bile duct injury. Cardiovasc Intervent Radiol. 2007;30:346.
9. de Reuver PR, Busch OR, Rauws EA, Lameris JS, van Gulik TM, Gouma DJ. Long-term results of a primary end-to-end anastomosis in peroperative detected bile duct injury. J Gastrointest Surg. 2007;11:296-302.
10. Mills JM, Tompkins RK, Zinner MJ, Longmire WP Jr, Roslyn JJ. Management of bile duct strictures. An evolving strategy. Arch Surg. 1992;127:1077-82.
11. Pellegrini CA, Thomas MJ, Way LW. Recurrent biliary stricture. Patterns of recurrence and outcome of surgical therapy. Am J Surg. 1984;147:175-89.
12. Zepeda-Gómez S, Baron TH. Benign biliary strictures: current endoscopic management. Nat Rev Gastroenterol Hepatol. 2011;8:573-81.
13. Kaasch C, Prat F, Liguori C, Meduri B, Ducot B, Fritsch J, et al. Endoscopic management of post-laparoscopic cholecystectomy biliary strictures. Long-term outcome in a multicenter study. Gastroenterol Clin Biol. 2006;30:124-9.
14. Mueller PR, vanSommenberg E, Ferrucci JT Jr, Weymann PJ, Butch RJ, Malt RA, et al. Biliary stricture dilatation: multicenter review of clinical management in 73 patients. Radiology. 1986;160:17-22.
15. Sacks D, McClenney TE, Cannela JF, Lewis CA. Society of Interventional Radiology clinical practice guidelines. J Vasc Interv Radiol. 2003;14:S199-202.
16. Lausch HU, Martin DF. Management of benign biliary strictures. Cardiovasc Intervent Radiol. 2002;25:657-66.
17. Chen MF, Jan YY, Wang CS, Hwang TL, Jeng LB, Chen SC, et al. A reappraisal of cholangiocarcinoma in patient with hepatolithiasis. Cancer. 1993;71:2461-5.
18. Yoon IJ, Sung KB, Song HY, Kang SG, Kim MH, Lee SG, et al. Benign biliary strictures associated with recurrent pyogenic cholangitis: treatment with expandable metallic stents. AJR Am J Roentgenol. 1997;169:1523-7.
19. A prospective analysis of 1518 laparoscopic cholecystectomies. The Southern Surgeons Club. N Engl J Med. 1991;324:1071-8.
20. Windsor JA, Pong J. Laparoscopic biliary injury: more than a learning curve problem. Aust N Z J Surg. 1998;68:186-9.
21. Cantwell CP, Pena CS, Gervais DA, Hahn PF, Dawson SL, Muller PR. Thirty years’ experience with balloon dilatation of benign postoperative biliary strictures: long-term outcomes. Radiology. 2000;219:1050-7.
22. Bonnel DH, Fingerhut AL. Percutaneous transhepatic balloon dilatation of benign biliary strictures: long-term results in 110 patients. Am J Surg. 2012;203:675-83.
23. Kucukay F, Okten RS, Yurdakul M, Ozdemir E, Erat S, Parlak E, et al. Long-term results of percutaneous biliary balloon dilatation treatment for benign hepatocojenostomy strictures: are repeated balloon dilations necessary? J Vasc Interv Radiol. 2012;23:1347-55.
24. Ramos-De la Medina A, Misra S, Lenoy AJ, Sarr MG. Management of benign biliary strictures by percutaneous interventional radiologic techniques (PIRT). HPB (Oxford). 2008;10:428-32.
25. Kimura K, Ohno M, Saisho H, Unozawa T, Tsuchiya Y, Morita M, et al. Association of gallbladder carcinoma and anomalous pancreasobiliary ductal union. Gastroenterology. 1985;89:1258-65.
26. Voyles CR, Smadja C, Shands WC, Blumgart LH. Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983;118:586-8.
27. Chijiiwa K, Koga A. Surgical management and long-term follow-up of patients with choledochal cysts. Am J Surg. 1993;165:238-42.
28. Itoi T, Khor CJ. Management of benign strictures of the extrahepatic bile duct due to chronic pancreatitis and surgical intervention. Dig Endosc. 2012;24 Suppl 1:8-16.
29. DePietro DM, Shlansky-Goldberg RD, Soulen MC, Stavropoulos SW, Mondschein JJ, Dadghi MS, et al. Long-term outcomes of a benign biliary stricture protocol. J Vasc Interv Radiol. 2015;26:1032-9.
30. Cerna M, Thomas RP, Köcher M, Përegin JH, Válek V, Havlík R, et al. Manometric perfusion test in biliary stricture treatment. Hepatogastroenterology. 2012;59:1354-8.
31. Savader SJ, Cameron JL, Lillemeke KD, Lund GB, Mitchell SE, Venhuzx AC. The bile duct manometric perfusion test and clinical trial: long-term predictive value of success after treatment of bile duct strictures: ten-year experience. J Vasc Interv Radiol. 1998;9:976-85.
32. Köcher M, Cerna M, Havlík R, Kril V, Gryga A, Duda M. Percutaneous treatment of benign bile duct strictures. Eur J Radiol. 2007;62:170-4.
33. VoS PM, van Beeck EJ, Smits NJ, Rauws EA, Gouma DJ, Reenders JW. Percutaneous balloon dilatation for benign hepatocojenostomy strictures. Abdom Imaging. 2000;25:134-8.
34. Duma R, Singh JR, Nag P, Rahela P, Rao GV, Reddy DN. Percutaneous management of benign hepatocojenostomy (HJ) strictures. Experience at a tertiary referral centre. J Gastroenterol Hepatol. 2011;26 Suppl 5:37.